Page 74 - Fisica In Medicina n° 1/2017

^Äëíê~Åí=jÉÇáÅá= =Linac-based extreme hypofractionation for localized prostate cancer with volumetric modulated radiation therapy: preliminary report of a phase ii studyF. Alongi1, S. Fersino1, A. Fiorentino1, R. Mazzola1, N. Giaj-Levra1, F. Ricchetti1, U. Tebano1,2, G. Sicignano1, S. Naccarato1, R. Ruggieri11 Division of Radiation Oncology, Sacro Cuore Don Calabria Hospital, Negrar (VR)IntroductionExtreme hypofractionation, also called stereotactic body radiation therapy (SBRT), in prostate cancer (PC) is a promising radiation treatment that delivers highly conformal doses in a few fractions, typically in 4 or 5 fractions. Aim of the present preliminary analysis of a phase-II prospective study is to evaluate the feasibility and preliminary side effects of SBRT in a cohort of localized PC patients.Materials and MethodsThe study, approved by the Ethical Committee, started on January 2014. Inclusion criteria were: age ≤ 80 years, World Health Organization performance status ≤ 2, histologically proven prostate adenocarcinoma, low-/intermediate-risk according to D'Amico criteria, no distant metastases, no previous surgery other than transurethral resection of the prostate (TURP), no other malignant tumor in the previous 5 years, a pre-SBRT International Prostatic Symptoms Score (IPSS) ranging between 0 and 7. The SBRT schedule was 35Gy for low risk and 37.5Gy for intermediate-risk PC in 5 fractions, delivered in consecutive days. SBRT was delivered with volumetric-modulated radiation therapy (VMAT). Toxicity assessment was performed according to CTCAE v4.0 scale. Neoadjuvant/concomitant hormonal therapy was prescribed according to risk classification.ResultsAt the time of analysis, forty-two patients were recruited in the protocol and treated. Median age was 74 years (range: 63-80) and median follow-up was 16 months (4-24). According to risk- category, 31/42 patients were low- risk and 11/42 were intermediate-risk. Median initial prostate-65